Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
33 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H1 2016 Summary
Global Markets Direct's, 'Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H1 2016', provides an overview of the Elephantiasis (Lymphatic Filariasis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Elephantiasis (Lymphatic Filariasis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Elephantiasis (Lymphatic Filariasis) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Elephantiasis (Lymphatic Filariasis) - The report reviews pipeline therapeutics for Elephantiasis (Lymphatic Filariasis) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Elephantiasis (Lymphatic Filariasis) therapeutics and enlists all their major and minor projects - The report assesses Elephantiasis (Lymphatic Filariasis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Elephantiasis (Lymphatic Filariasis) Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Elephantiasis (Lymphatic Filariasis) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Elephantiasis (Lymphatic Filariasis) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Elephantiasis (Lymphatic Filariasis) Overview 6 Therapeutics Development 7 Pipeline Products for Elephantiasis (Lymphatic Filariasis) - Overview 7 Pipeline Products for Elephantiasis (Lymphatic Filariasis) - Comparative Analysis 8 Elephantiasis (Lymphatic Filariasis) - Therapeutics under Development by Companies 9 Elephantiasis (Lymphatic Filariasis) - Therapeutics under Investigation by Universities/Institutes 10 Elephantiasis (Lymphatic Filariasis) - Pipeline Products Glance 11 Early Stage Products 11 Elephantiasis (Lymphatic Filariasis) - Products under Development by Companies 12 Elephantiasis (Lymphatic Filariasis) - Products under Investigation by Universities/Institutes 13 Elephantiasis (Lymphatic Filariasis) - Companies Involved in Therapeutics Development 14 Anacor Pharmaceuticals, Inc. 14 Eisai Co., Ltd. 15 Johnson & Johnson 16 Elephantiasis (Lymphatic Filariasis) - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Target 18 Assessment by Mechanism of Action 19 Assessment by Molecule Type 20 Drug Profiles 22 filariasis vaccine - Drug Profile 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 flubendazole - Drug Profile 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 IIC-942A001 - Drug Profile 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 IIC-950A001 - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 lymphatic filariasis vaccine - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 S-0112091 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Small Molecule for Lymphatic Filariasis - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Small Molecules for Lymphatic Filariasis and Onchocerciasis - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Small Molecules for Nematodal Diseases - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Appendix 32 Methodology 32 Coverage 32 Secondary Research 32 Primary Research 32 Expert Panel Validation 32 Contact Us 32 Disclaimer 33
List of Tables
Number of Products under Development for Elephantiasis (Lymphatic Filariasis), H1 2016 7 Number of Products under Development for Elephantiasis (Lymphatic Filariasis) - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Number of Products under Investigation by Universities/Institutes, H1 2016 10 Comparative Analysis by Early Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 Products under Investigation by Universities/Institutes, H1 2016 13 Elephantiasis (Lymphatic Filariasis) - Pipeline by Anacor Pharmaceuticals, Inc., H1 2016 14 Elephantiasis (Lymphatic Filariasis) - Pipeline by Eisai Co., Ltd., H1 2016 15 Elephantiasis (Lymphatic Filariasis) - Pipeline by Johnson & Johnson, H1 2016 16 Assessment by Monotherapy Products, H1 2016 17 Number of Products by Stage and Target, H1 2016 18 Number of Products by Stage and Mechanism of Action, H1 2016 19 Number of Products by Stage and Molecule Type, H1 2016 21
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.